Conjunctivitis in Medical Technology

Alcon Commences Phase 2 Clinical Trial of NovaBay's NVC-422 for Viral Conjunctivitis

... for viral conjunctivitis, a type of "pink eye". conjunctivitis is a pervasive and painful condition that affects ... traditional antibiotics. The Phase 2 viral conjunctivitis study follows a recently completed Phase 1 trial ... the first effective product to address viral conjunctivitis for which there are limited treatment options." ...

ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting

... clinically effective in reducing ocular itching associated with allergic conjunctivitis in the CAC model for at least 8 hours after dosing and statistically ... in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic conjunctivitis Authors: J.A. Gow, G.L. Torkildsen, J.I. Williams, P.J. Gomes, M.B. ...

Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis

... been treated effectively and safely by Prednisporin(TM)." Allergic conjunctivitis is a frequent disorder. It occurs in up to 90% of patients suffering from ... surface allergy and inflammation. More than 50% of all forms of allergic conjunctivitis have a chronic inflammatory background (persistent allergic ...

Inspire Announces Presentations at 2007 Association for Research in Vision and Ophthalmology Annual Meeting

... AzaSite(TM)(azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and ...

Inspire Announces Positive Results of Phase 2 Trial of Epinastine Nasal Spray for Seasonal Allergic Rhinitis

... AzaSite (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and ...

ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine

... in this press release related to the prospects and timing of further development of bepotastine, the potential of bepotastine of treating allergic conjunctivitis and of providing allergy sufferers with comprehensive protection for the treatment of their ophthalmic and nasal symptoms, the potential ...

Inspire Announces Presentations at Two European Scientific Conferences

... AzaSite(TM) (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and ...

Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

... AzaSite(TM) (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and ...